You seem to infer that the company's only pathway to success or additional funding is on the back of the pediatrics FDA outcome for Remestemcel-L / sr-GVHD ?
You clearly overlooked the fact that the CHF FDA meeting has finally taken place and Mesoblast will receive the minutes next month (March) - that will have an impact on funding / partnership for that indication so there are potential $ there ......
...... and then of course the 17th March due date for the 122 million shares / overhang from the CR in December will most likely be awarded to a CLBP partner so I am not as worried about $$ as you seem to be - I still anticipate if they receive enough money through the sale of these remaining shares (at a likely premium to 30 cents for a decent stake in the company) they will more than likely payout Oaktree but I guess we will see if and when these shares find a home ?
GLTAH
MSB Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)